Time filter

Source Type

Patent
Shanghai Haiyan Pharmaceutical Technology Co. and Yangtze River Pharmaceutical Group Co. | Date: 2015-04-13

The present invention relates to 2,3,4,6-tetra-substituted benzene-1,5-diamine derivatives, a preparation method therefor and a medicinal use thereof. Specifically, disclosed are compounds of formula (I) or pharmaceutically acceptable salts, stereoisomers, solvates or prodrugs, preparation method therefor and application thereof. Definition of each group in the formula can be found in the specification for details.


Patent
Shanghai Haiyan Pharmaceutical Technology Co. and Yangtze River Pharmaceutical Group Co. | Date: 2017-03-22

The present invention relates to 2,3,4,6-tetra-substituted benzene-1,5-diamine derivatives, a preparation method therefor and a medicinal use thereof. Specifically, disclosed are compounds of formula (I) or pharmaceutically acceptable salts, stereoisomers, solvates or prodrugs, preparation method therefor and application thereof. Definition of each group in the formula can be found in the specification for details.


Patent
Shanghai Haiyan Pharmaceutical Technology Co. and Yangtze River Pharmaceutical Group Co. | Date: 2017-01-11

The present invention discloses a series of piperidine derivatives as orexin receptor antagonists and compositions thereof, and relates to the application thereof in preparing medications for the treatment of insomnia, chronic obstructive pulmonary disease, obstructive sleep apnea, hypersomnia, anxiety, obsessive-compulsive disorder, panic attack, nicotine addiction, or binge eating disorder.


Patent
Shanghai Haiyan Pharmaceutical Technology Co. and Yangtze River Pharmaceutical Group Co. | Date: 2017-01-04

The present invention provides a class of 2,4-substituted phenylene-1,5-diamine derivatives, having an inhibiting effect on EGFR tyrosine kinases, and pharmaceutically acceptable salt, stereoisomer, solvate or prodrug of said derivatives. See the description for the definition of each group in the formula. In addition, the present invention also discloses pharmaceutical compositions, pharmaceutically acceptable compositions and applications thereof.


Patent
Shanghai Haiyan Pharmaceutical Technology Co. and Yangtze River Pharmaceutical Group Co. | Date: 2017-05-31

The present invention relates to a 2,4-disubstituted 7H-pyrrolo[2,3-d]pyrimidine derivative, a preparation method and a medicinal use thereof. In particular, the present invention discloses a compound of formula (I) or a pharmaceutically acceptable salt, stereoisomer, solvate or prodrug thereof, and a preparation method and use thereof. For the definition of each group in formula (I), see the description for details.


PubMed | Shanghai Haini Pharmaceutical Co., Yangtze River Pharmaceutical Group Co. and Shanghai Institute of Technology
Type: Journal Article | Journal: Biomedical chromatography : BMC | Year: 2015

A high-performance liquid chromatography coupled with quadrupole time-of-flight mass tandem mass spectrometry method was established to characterize the chemical constituents of Kangxianling granule (KXL), a traditional Chinese medicine formula, and the metabolic profile in rat urine and plasma after oral administration of KXL. A total of 27 compounds in KXL extract and 13 prototype compounds with 12 metabolites in rat urine and plasma were identified. Among the 27 detected compounds, 15 were identified by comparing the retention time and MS data with that of reference compounds and the other 12 compounds were tentatively assigned based on the MS data and reference literature. The main prototype components absorbed in rat were amygdalin, salvianolic acid B, tanshinones and anthraquinones. Hydroxylation, glucuronidation and sulfation were the principal metabolic pathways in rat. The results revealed that the 25 compounds identified in rat urine and plasma were the potential active ingredients of KXL, which provides helpful chemical information for further study of the pharmacology mechanism of KXL.


PubMed | Shanghai Haini Pharmaceutical Co., Yangtze River Pharmaceutical Group Co. and Shanghai Institute of Technology
Type: Journal Article | Journal: Journal of chromatographic science | Year: 2015

A high-performance liquid chromatography/quadrupole time-of-flight mass spectrometry method was established to detect as many constituents in rat biological fluids as possible after oral administration of Qing Ru Xiao granules (QRX). An Agilent Poroshell 120 EC-C18 column was adopted to separate the sample constituents, and mass spectra were acquired in positive and negative ion modes. First, the fingerprints of QRX were established, resulting in 28 components being detected within 30 min. Among these compounds, 11 were tentatively identified by comparing the retention times and mass spectral data with those of reference standards and the reference literature; the other 17 components were tentatively assigned solely based on the mass spectrometry data. Furthermore, metabolites in rat plasma and urine after oral administration of QRX were also analyzed. A total of 15 compounds were identified, including 13 prototypes and 2 metabolites through metabolic pathways of oxidation. This is the first systematic study on the metabolic profiling of QRX.


Zheng L.,Yangtze River Pharmaceutical Group Co. | Zhou Y.,Yangtze River Pharmaceutical Group Co. | Zhang J.-Y.,Beijing University of Chinese Medicine | Song M.,Yangtze River Pharmaceutical Group Co. | And 3 more authors.
Chinese Journal of Natural Medicines | Year: 2014

Aim: To investigate the chemical constituents of Dioscorea zingiberensis C. H. Wright. Methods: The compounds were isolated by various chromatographic techniques, and the structures of the new steroidal saponins were elucidated by extensive 1D- and 2D-NMR, MS, and IR spectral analysis. Results: The 70% EtOH extract of the rhizomes of Dioscorea zingiberensis afforded two new steroidal saponins, zingiberenosides A (1) and B (2), along with eight known analogues, 3β, 26-dihydroxy-25(R)-furosta-δ5, 20(22)-diene-3-O-α-L- rhamnopyranosyl-(1→2)-O-β-D-glucopyranoside (3), methyl parvifloside (4), deltoside (5), methyl deltoside (6), zingiberensis new saponin (7), deltonin (8), progenin III (9) and diosgenin-diglucoside (10). Conclusion: Two new steroidal saponins were isolated from Dioscorea zingiberensis and their structures determined. © 2014 China Pharmaceutical University.


Patent
SHANGHAI HAIYAN PHARMACEUTICAL TECHNOLOGY Co. and Yangtze River Pharmaceutical Group Co. | Date: 2015-02-13

The present invention provides a class of 2,4-substituted phenylene-1,5-diamine derivatives, having an inhibiting effect on EGFR tyrosine kinases, and pharmaceutically acceptable salt, stereoisomer, solvate or prodrug of said derivatives. See the description for the definition of each group in the formula. In addition, the present invention also discloses pharmaceutical compositions, pharmaceutically acceptable compositions and applications thereof.


Patent
Yangtze River Pharmaceutical Group Co., TIANJIN NORTH PHARMA Science and Technology CO. | Date: 2010-01-11

The invention relates to the compounds of formula I, their preparation and the pharmaceutical compositions containing the compounds. The invention also relates to the use of the compounds of formula I in preparing medicines, which can treat sexual dysfunction of animals including human (male and female), especially erectile dysfunction of male and the diseases in which the function of phospholipase 5 (cGMP PDE5) is involved.

Loading Yangtze River Pharmaceutical Group Co. collaborators
Loading Yangtze River Pharmaceutical Group Co. collaborators